NCT01475058View on ClinicalTrials.gov

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

July 31, 2014

Conditions
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

allogeneic cytomegalovirus-specific cytotoxic T lymphocytes

Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01475058 - CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | Biotech Hunter | Biotech Hunter